{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T07:59:20Z","timestamp":1789545560934,"version":"build-2803163510"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2022,9,28]],"date-time":"2022-09-28T00:00:00Z","timestamp":1664323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2022,9,28]],"date-time":"2022-09-28T00:00:00Z","timestamp":1664323200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100005205","name":"Janssen Research and Development","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005205","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pediatr Drugs"],"published-print":{"date-parts":[[2022,11]]},"DOI":"10.1007\/s40272-022-00533-y","type":"journal-article","created":{"date-parts":[[2022,9,28]],"date-time":"2022-09-28T14:02:38Z","timestamp":1664373758000},"page":"699-714","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Intravenous Golimumab in Patients with Polyarticular Juvenile Idiopathic Arthritis and Juvenile Psoriatic Arthritis and Subcutaneous Ustekinumab in Patients with Juvenile Psoriatic Arthritis: Extrapolation of Data from Studies in Adults and Adjacent Pediatric Populations"],"prefix":"10.1007","volume":"24","clinical-trial-number":[{"clinical-trial-number":"nct02277444","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01090427","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02698475","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Jocelyn H.","family":"Leu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalie J.","family":"Shiff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Clark","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Bensley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathleen G.","family":"Lomax","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine","family":"Berezny","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert M.","family":"Nelson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Honghui","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenhua","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,9,28]]},"reference":[{"key":"533_CR1","unstructured":"Pediatric Research Equity Act (PREA). 2003:Pub L No. 108-55."},{"key":"533_CR2","unstructured":"International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. ICH E11A: Pediatric extrapolation. April 4, 2022. Available at: https:\/\/database.ich.org\/sites\/default\/files\/ICH_E11A_Document_Step2_Guideline_2022_0404_0.pdf. Accessed 6 Apr 2022."},{"key":"533_CR3","first-page":"390","volume":"31","author":"RE Petty","year":"2004","unstructured":"Petty RE, Southwood TR, Manners P, Baum J, Glass DN, Goldenberg J, He X, Maldonado-Cocco J, Orozco-Alcala J, Prieur AM, Suarez-Almazor ME, Woo P, International League of Associations for Rheumatology. International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001. J Rheumatol. 2004;31:390\u20132.","journal-title":"J Rheumatol"},{"key":"533_CR4","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1002\/art.40884","volume":"71","author":"S Ringold","year":"2019","unstructured":"Ringold S, Angeles-Han ST, Beukelman T, Lovell DJ, Cuello CA, Becker ML, Colbert RA, Feldman BM, Ferguson PJ, Gewanter HL, Guzman J, Horonjeff J, Nigrovic PA, Ombrello M, Passo M, Stoll ML, Rabinovich CE, Schneider R, Halyabar O, Hays K, Shah AA, Sullivan N, Szymanski AM, Turgunbaev M, Turner A, Reston J. 2019 American College of Rheumatology\/Arthritis Foundation Guideline for the treatment of juvenile idiopathic arthritis: therapeutic approaches for non-systemic polyarthritis, sacroiliitis, and enthesitis. Arthritis Rheumatol. 2019;71:846\u201363. https:\/\/doi.org\/10.1002\/art.40884.","journal-title":"Arthritis Rheumatol"},{"key":"533_CR5","unstructured":"European Medicines Agency. Guideline on clinical investigation of medicinal products for the treatment of juvenile idiopathic arthritis. EMA\/CHMP\/239770\/2014 Rev 2. November 19, 2015. https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/guideline-clinical-investigation-medicinal-products-treatment-juvenile-idiopathic-arthritis_en.pdf. Accessed 29 Mar 2022."},{"key":"533_CR6","doi-asserted-by":"publisher","first-page":"2138","DOI":"10.1016\/S0140-6736(11)60244-4","volume":"377","author":"B Prakken","year":"2011","unstructured":"Prakken B, Albani S, Martini A. Juvenile idiopathic arthritis. Lancet. 2011;377:2138\u201349.","journal-title":"Lancet"},{"key":"533_CR7","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.jbspin.2013.09.003","volume":"81","author":"S Thierry","year":"2014","unstructured":"Thierry S, Fautrel B, Lemelle I, Guillemin F. Prevalence and incidence of juvenile idiopathic arthritis: a systematic review. Jt Bone Spine. 2014;81:112\u20137.","journal-title":"Jt Bone Spine"},{"key":"533_CR8","doi-asserted-by":"publisher","first-page":"1945","DOI":"10.1002\/art.41390","volume":"72","author":"HI Brunner","year":"2020","unstructured":"Brunner HI, Schanberg LE, Kimura Y, Dennos A, Co DO, Colbert RA, Fuhlbrigge R, Goldmuntz E, Kingsbury DJ, Patty-Resk C, Mintz S, Onel K, Rider LG, Schneider R, Watts A, von Scheven E, Lovell DJ, Beukelman T, PRCSG Advisory Council and the CARRA Registry Investigators. New medications are needed for children with juvenile idiopathic arthritis. Arthritis Rheumatol. 2020;72:1945\u201351. https:\/\/doi.org\/10.1002\/art.41390.","journal-title":"Arthritis Rheumatol"},{"key":"533_CR9","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1002\/acr.22583","volume":"67","author":"R Aggarwal","year":"2015","unstructured":"Aggarwal R, Ringold S, Khanna D, Neogi T, Johnson SR, Miller A, Brunner HI, Ogawa R, Felson D, Ogdie A, Aletaha D, Feldman BM. Distinctions between diagnostic and classification criteria? Arthritis Care Res (Hoboken). 2015;67:891\u20137.","journal-title":"Arthritis Care Res (Hoboken)."},{"key":"533_CR10","first-page":"257","volume":"17","author":"PA Nigrovic","year":"2021","unstructured":"Nigrovic PA, Colbert RA, Holers VM, Ozen S, Ruperto N, Thompson SD, Wedderburn LR, Yeung RSM, Martini A. Biological classification of childhood arthritis: roadmap to a molecular nomenclature. Nat Rev. 2021;17:257\u201369.","journal-title":"Nat Rev"},{"key":"533_CR11","doi-asserted-by":"publisher","first-page":"190","DOI":"10.3899\/jrheum.180168","volume":"46","author":"A Martini","year":"2019","unstructured":"Martini A, Ravelli A, Avcin T, Beresford MW, Burgos-Vargas R, Cuttica R, Ilowite NT, Khubchandani R, Laxer RM, Lovell DJ, Petty RE, Wallace CA, Wulffraat NM, Pistorio A, Ruperto N, for the Pediatric Rheumatology International Trials Organization (PRINTO). Toward new classification criteria for juvenile idiopathic arthritis: first steps, pediatric rheumatology international trials organization international consensus. J Rheumatol. 2019;46:190\u20137.","journal-title":"J Rheumatol"},{"key":"533_CR12","doi-asserted-by":"publisher","first-page":"952","DOI":"10.1136\/archdischild-2016-312259","volume":"102","author":"AM Stefanska","year":"2017","unstructured":"Stefanska AM, Distlerov\u00e1 D, Musaus J, Olski TM, Dunder K, Salmonson T, Mentzer D, M\u00fcller-Berghaus J, Hemmings R, Vesel\u00fd R. Extrapolation in the development of paediatric medicines: examples from approvals for biological treatments for paediatric chronic immune-mediated inflammatory diseases. Arch Dis Child. 2017;102:952\u20137.","journal-title":"Arch Dis Child"},{"key":"533_CR13","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1097\/BOR.0b013e328348b278","volume":"23","author":"ML Stoll","year":"2011","unstructured":"Stoll ML, Punaro M. Psoriatic juvenile idiopathic arthritis: a tale of two subgroups. Curr Opin Rheumatol. 2011;23:437\u201343.","journal-title":"Curr Opin Rheumatol"},{"key":"533_CR14","doi-asserted-by":"publisher","first-page":"11","DOI":"10.3899\/jrheum.180131","volume":"94","author":"D Zisman","year":"2018","unstructured":"Zisman D, Stoll ML, Butbul Aviel Y, Mellins ED. Juvenile psoriatic arthritis: a report from the GRAPPA 2017 annual meeting. J Rheumatol Suppl. 2018;94:11\u20136.","journal-title":"J Rheumatol Suppl"},{"key":"533_CR15","unstructured":"United States Food and Drug Administration. Accelerating drug development for polyarticular juvenile idiopathic arthritis (pJIA). October 2, 2019. https:\/\/www.fda.gov\/news-events\/fda-meetings-conferences-and-workshops\/accelerating-drug-development-polyarticular-juvenile-idiopathic-arthritis-pjia-10022019-10022019. Accessed 16 Mar 2022."},{"key":"533_CR16","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1002\/cpt.2218","volume":"110","author":"R Singh","year":"2021","unstructured":"Singh R, Ivaturi VD, Penzenstadler J, Liu T, Chen J, Marathe A, Ji P, Glaser R, Nikolov N, Sahajwalla C. Response similarity assessment between polyarticular juvenile idiopathic arthritis and adult rheumatoid arthritis for biologics. Clin Pharm Ther. 2021;110:98\u2013107.","journal-title":"Clin Pharm Ther"},{"key":"533_CR17","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1136\/archdischild-2017-312994","volume":"102","author":"N Ruperto","year":"2017","unstructured":"Ruperto N, Brunner HI, Lovell DJ, Martini A, for the Paediatric Rheumatology International Trials Organisation (PRINTO) and the Pediatric Rheumatology Collaborative Study Group (PRCSG). Extrapolation or controlled trials in paediatrics: the current dilemma. Arch Dis Child. 2017;102:949\u201351.","journal-title":"Arch Dis Child"},{"key":"533_CR18","unstructured":"United States Food and Drug Administration. NDA\/BLA multi-disciplinary review and evaluation, BLA 25433, Supplement 30, IV golimumab (Simponi Aria) for pJIA. October 12, 2018. https:\/\/www.fda.gov\/media\/143318\/download. Accessed 18 July 2022."},{"key":"533_CR19","doi-asserted-by":"publisher","first-page":"4495","DOI":"10.1093\/rheumatology\/keab021","volume":"60","author":"N Ruperto","year":"2021","unstructured":"Ruperto N, Brunner HI, Pacheco-Tena C, Louw I, Vega-Cornejo G, Spindler AJ, Kingsbury DJ, Schmeling H, Borzutzky A, Cuttica R, Inman CJ, Malievskiy V, Scott C, Keltsev V, Terreri MT, Viola DO, Xavier RM, Pedrosa Fernandes TA, del Roc\u00edo Maldonado Vel\u00e1zquez M, Henrickson M, Clark MB, Bensley KA, Li X, Lo KH, Leu JH, Hsu C-H, Hsia EC, Xu Z, Martini A, Lovell DJ, for the Pediatric Rheumatology Collaborative Study Group (PRCSG) and the Paediatric Rheumatology International Trials Organisation (PRINTO). Open-label phase 3 study of intravenous golimumab in patients with polyarticular juvenile idiopathic arthritis. Rheumatology. 2021;60:4495\u2013507.","journal-title":"Rheumatology"},{"key":"533_CR20","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1136\/annrheumdis-2012-201411","volume":"72","author":"ME Weinblatt","year":"2013","unstructured":"Weinblatt ME, Bingham CO III, Mendelsohn AM, Kim L, Mack M, Lu J, Baker D, Westhovens R. Intravenous golimumab is effective in patients with active rheumatoid arthritis despite methotrexate therapy with responses as early as week 2: results of the phase 3, randomised, multicentre, double-blind, placebo-controlled GO-FURTHER trial. Ann Rheum Dis. 2013;72:381\u20139.","journal-title":"Ann Rheum Dis"},{"key":"533_CR21","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1002\/art.27348","volume":"62","author":"J Kremer","year":"2010","unstructured":"Kremer J, Ritchlin C, Mendelsohn A, Baker D, Kim L, Xu Z, Han J, Taylor P. Golimumab, a new human anti-tumor necrosis factor \u03b1 antibody, administered intravenously in patients with active rheumatoid arthritis: forty-eight-week efficacy and safety results of a phase III randomized, double-blind, placebo-controlled study. Arthritis Rheum. 2010;62:917\u201328.","journal-title":"Arthritis Rheum"},{"key":"533_CR22","doi-asserted-by":"publisher","first-page":"2151","DOI":"10.1002\/art.40226","volume":"69","author":"A Kavanaugh","year":"2017","unstructured":"Kavanaugh A, Husni ME, Harrison DD, Kim L, Lo KH, Leu JH, Hsia EC. Safety and efficacy of intravenous golimumab in patients with active psoriatic arthritis. Arthritis Rheumatol. 2017;69:2151\u201361.","journal-title":"Arthritis Rheumatol"},{"key":"533_CR23","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1016\/j.jaad.2015.07.002","volume":"73","author":"I Landells","year":"2015","unstructured":"Landells I, Marano C, Hsu M-C, Li S, Zhu Y, Eichenfield LF, Hoeger PH, Menter A, Paller AS, Taieb A, Philipp S, Szapary P, Randazzo B. Ustekinumab in adolescent patients age 12 to 17 years with moderate-to-severe plaque psoriasis: results of the randomized phase 3 CADMUS study. J Am Acad Dermatol. 2015;73:594\u2013603.","journal-title":"J Am Acad Dermatol"},{"key":"533_CR24","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1111\/bjd.19018","volume":"183","author":"S Philipp","year":"2020","unstructured":"Philipp S, Menter A, Nikkels AF, Barber K, Landells I, Eichenfield LF, Song M, Randazzo B, Li S, Hsu M-C, Zhu Y, DePrimo S, Paller AS. Ustekinumab for the treatment of moderate-to-severe plaque psoriasis in paediatric patients (\u22656 to <12 years of age): efficacy, safety, pharmacokinetic and biomarker results from the open-label CADMUS Jr study. Br J Dermatol. 2020;183:664\u201372.","journal-title":"Br J Dermatol"},{"key":"533_CR25","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1016\/S0140-6736(13)60594-2","volume":"382","author":"IB McInnes","year":"2013","unstructured":"McInnes IB, Kavanaugh A, Gottlieb AB, Puig L, Rahman P, Ritchlin C, Brodmerkel C, Li S, Wang Y, Mendelsohn AM, Doyle MK, on behalf of the PSUMMIT 1 Study Group. Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial. Lancet. 2013;382:780\u20139.","journal-title":"Lancet"},{"key":"533_CR26","doi-asserted-by":"publisher","first-page":"990","DOI":"10.1136\/annrheumdis-2013-204655","volume":"73","author":"C Ritchlin","year":"2014","unstructured":"Ritchlin C, Rahman P, Kavanaugh A, McInnes IB, Puig L, Li S, Wang Y, Shen Y-K, Doyle MK, Mendelsohn AM, Gottlieb AB, on behalf of the PSUMMIT 2 Study Group. Efficacy and safety of the anti-IL-12\/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional non-biological and biological anti-tumour necrosis factor therapy: 6-month and 1-year results of the phase 3, multicentre, double-blind, placebo-controlled, randomised PSUMMIT 2 trial. Ann Rheum Dis. 2014;73:990\u20139.","journal-title":"Ann Rheum Dis"},{"key":"533_CR27","doi-asserted-by":"publisher","first-page":"1552","DOI":"10.1111\/bjd.15722","volume":"177","author":"A Blauvelt","year":"2017","unstructured":"Blauvelt A, Ferris LK, Yamauchi PS, Qureshi A, Leonardi CL, Farahi K, Fakharzadeh S, Hsu MC, Li S, Chevrier M, Smith K, Goyal K, Chen Y, Mu\u00f1oz-El\u00edas EJ, Callis DK. Extension of ustekinumab maintenance dosing interval in moderate-to-severe psoriasis: results of a phase IIIb, randomized, double-blinded, active-controlled, multicentre study (PSTELLAR). Br J Dermatol. 2017;177:1552\u201361.","journal-title":"Br J Dermatol"},{"key":"533_CR28","doi-asserted-by":"publisher","first-page":"2191","DOI":"10.1001\/jama.2013.281053","volume":"310","author":"World Medical Association","year":"2013","unstructured":"World Medical Association. World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. J Am Med Assoc. 2013;310:2191\u20134.","journal-title":"J Am Med Assoc"},{"key":"533_CR29","unstructured":"International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. Integrated addendum to ICH E6(R1): guideline for Good Clinical Practice E6(R2). 2016. Available at: https:\/\/database.ich.org\/sites\/default\/files\/E6_R2_Addendum.pdf. Accessed 16 Mar 2022."},{"issue":"6","key":"533_CR30","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1002\/art.1780380602","volume":"38","author":"DT Felson","year":"1995","unstructured":"Felson DT, Anderson JJ, Boers M, Bombardier C, Furst D, Goldsmith C, Katz LM, Lightfoot R Jr, Paulus H, Strand V, Tugwell P, Weinblatt M, Williams HJ, Wolfe F, Kieszak S. American College of Rheumatology preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum. 1995;38(6):727\u201335.","journal-title":"Arthritis Rheum"},{"key":"533_CR31","doi-asserted-by":"publisher","first-page":"1202","DOI":"10.1002\/1529-0131(199707)40:7<1202::AID-ART3>3.0.CO;2-R","volume":"40","author":"EH Giannini","year":"1997","unstructured":"Giannini EH, Ruperto N, Ravelli A, Lovell DJ, Felson DT, Martini A. Preliminary definition of improvement in juvenile arthritis. Arthritis Rheumatol. 1997;40:1202\u20139.","journal-title":"Arthritis Rheumatol"},{"issue":"2","key":"533_CR32","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2016-000304","volume":"2","author":"F Oliveira-Ramos","year":"2016","unstructured":"Oliveira-Ramos F, Eus\u00e9bio M, Martins FM, Mour\u00e3o AF, Furtado C, Campanilho-Marques R, Cordeiro I, Ferreira J, Cerqueira M, Figueira R, Brito I, Canh\u00e3o H, Santos MJ, Melo-Gomes JA, Fonseca JE. Juvenile idiopathic arthritis in adulthood: fulfilment of classification criteria for adult rheumatic diseases, long-term outcomes and predictors of inactive disease, functional status and damage. RMD Open. 2016;2(2): e000304.","journal-title":"RMD Open"},{"key":"533_CR33","unstructured":"Simponi Aria (golimumab injection, for intravenous use). Package insert. Horsham: Janssen Biotech, Inc.; 2021."},{"key":"533_CR34","unstructured":"Simponi (golimumab for injection). Package insert. Horsham: Janssen Biotech, Inc.; 2019."},{"key":"533_CR35","doi-asserted-by":"publisher","first-page":"341","DOI":"10.3899\/jrheum.170487","volume":"45","author":"A Deodhar","year":"2018","unstructured":"Deodhar A, Reveille JD, Harrison DD, Kim L, Lo KH, Leu JH, Hsia EC. Safety and efficacy of golimumab administered intravenously in adults with ankylosing spondylitis: results through week 28 of the GO-ALIVE study. J Rheumatol. 2018;45:341\u20138 (Erratum in: J Rheumatol. 2018;45:291).","journal-title":"J Rheumatol"},{"key":"533_CR36","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1136\/annrheumdis-2016-210456","volume":"77","author":"HI Brunner","year":"2018","unstructured":"Brunner HI, Ruperto N, Tzaribachev N, Horneff G, Chasnyk VG, Panaviene V, Abud-Mendoza C, Reiff A, Alexeeva E, Rubio-P\u00e9rez N, Keltsev V, Kingsbury DJ, del Rocio Maldonado Vel\u00e1zquez M, Nikishina I, Silverman ED, Joos R, Smolewska E, Bandeira M, Minden K, van Royen-Kerkhof A, Emminger W, Foeldvari I, Lauwerys BR, Sztajnbok F, Gilmer KE, Xu Z, Leu JH, Kim L, Lamberth SL, Loza MJ, Lovell DJ, Martini A. Subcutaneous golimumab for children with active polyarticular-course juvenile idiopathic arthritis: results of a multicentre, double-blind, randomised-withdrawal trial. Ann Rheum Dis. 2018;77:21\u20139.","journal-title":"Ann Rheum Dis"},{"key":"533_CR37","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1159\/000250839","volume":"157","author":"T Fredriksson","year":"1978","unstructured":"Fredriksson T, Pettersson U. Severe psoriasis\u2014oral therapy with a new retinoid. Dermatologica. 1978;157:238\u201344.","journal-title":"Dermatologica"},{"key":"533_CR38","unstructured":"Stelara (ustekinumab). Package insert. Horsham: Janssen Biotech, Inc.; 2020."},{"key":"533_CR39","doi-asserted-by":"publisher","first-page":"1931","DOI":"10.1093\/ecco-jcc\/jjab089","volume":"15","author":"JR Rosh","year":"2021","unstructured":"Rosh JR, Turner D, Griffiths A, Cohen SA, Jacobstein D, Adedokun OJ, Padgett L, Terry NA, O\u2019Brien C, Hyams JS. Ustekinumab in paediatric patients with moderately to severely active Crohn\u2019s disease: pharmacokinetics, safety, and efficacy results from UniStar, a phase 1 study. J Crohn\u2019s Colitis. 2021;15:1931\u201342.","journal-title":"J Crohn\u2019s Colitis."},{"key":"533_CR40","unstructured":"Humira (adalimumab). Package insert. North Chicago: AbbVie Inc.; 2021."},{"key":"533_CR41","unstructured":"Enbrel (etanercept). Package insert. Thousand Oaks: Immunex Corporation; 2021."},{"key":"533_CR42","unstructured":"Remicade (infliximab). Package insert. Horsham: Janssen Biotech, Inc.; 2021."},{"key":"533_CR43","unstructured":"Cimzia (certolizumab pegol). Package insert. Smyrna: UCB, Inc.; 2019."},{"key":"533_CR44","doi-asserted-by":"publisher","first-page":"S31","DOI":"10.1097\/00006454-200005001-00006","volume":"19","author":"KA Daly","year":"2000","unstructured":"Daly KA, Giebink GS. Clinical epidemiology of otitis media. Pediatr Infect Dis J. 2000;19:S31\u20136.","journal-title":"Pediatr Infect Dis J"},{"key":"533_CR45","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1093\/aje\/154.7.666","volume":"154","author":"MAS De Wit","year":"2001","unstructured":"De Wit MAS, Koopmans MPG, Kortbeek LM, Wannet WJ, Vinj\u00e9 J, van Leusden F, Bartelds AIM, van Duynhoven YTHP. Sensor, a population-based cohort study on gastroenteritis in the Netherlands: incidence and etiology. Am J Epidemiol. 2001;154:666\u201374.","journal-title":"Am J Epidemiol"},{"key":"533_CR46","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1007\/s00405-015-3872-6","volume":"273","author":"JP Windfuhr","year":"2016","unstructured":"Windfuhr JP, Toepfner N, Steffen G, Walsfahrer F, Berner R. Clinical practice guideline: tonsillitis I. Diagnostics and nonsurgical management. Eur Arch Otorhinolaryngol. 2016;273:973\u201387.","journal-title":"Eur Arch Otorhinolaryngol"},{"key":"533_CR47","doi-asserted-by":"publisher","first-page":"1665","DOI":"10.1016\/S0140-6736(08)60725-4","volume":"371","author":"CL Leonardi","year":"2008","unstructured":"Leonardi CL, Kimball AB, Papp KA, Yeilding N, Guzzo C, Wang Y, Li S, Dooley LT, Gordon KB, PHOENIX 1 study investigators. Efficacy and safety of ustekinumab, a human interleukin-12\/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1). Lancet. 2008;371:1665\u201374.","journal-title":"Lancet"},{"key":"533_CR48","doi-asserted-by":"publisher","first-page":"1675","DOI":"10.1016\/S0140-6736(08)60726-6","volume":"371","author":"KA Papp","year":"2008","unstructured":"Papp KA, Langley RG, Lebwohl M, Krueger GG, Szapary P, Yeilding N, Guzzo C, Hsu M-C, Wang Y, Li S, Dooley LT, Reich K, PHOENIX 2 Study Investigators. Efficacy and safety of ustekinumab, a human interleukin-12\/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2). Lancet. 2008;371:1675\u201384.","journal-title":"Lancet"},{"key":"533_CR49","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1016\/j.clinthera.2014.09.012","volume":"37","author":"Z Xu","year":"2015","unstructured":"Xu Z, Marciniak SJ, Frederick B, Kim L, Zhuang Y, Davis HM, Zhou H. Pharmacokinetic bridging approach for developing biologics-delivery devices: a case study with a golimumab autoinjector. Clin Ther. 2015;37:427\u201338.","journal-title":"Clin Ther"},{"key":"533_CR50","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1007\/s40262-015-0361-4","volume":"55","author":"KL Gill","year":"2016","unstructured":"Gill KL, Machavaram KK, Rose RH, Chetty M. Potential sources of inter-subject variability in monoclonal antibody pharmacokinetics. Clin Pharmacokinet. 2016;55:789\u2013805.","journal-title":"Clin Pharmacokinet"},{"key":"533_CR51","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/j.pharmthera.2012.10.005","volume":"137","author":"Z Xu","year":"2013","unstructured":"Xu Z, Davis HM, Zhou H. Rational development and utilization of antibody-based therapeutic proteins in pediatrics. Pharmacol Ther. 2013;137:225\u201347.","journal-title":"Pharmacol Ther"}],"container-title":["Pediatric Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40272-022-00533-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40272-022-00533-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40272-022-00533-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,24]],"date-time":"2022-10-24T22:13:48Z","timestamp":1666649628000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40272-022-00533-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,28]]},"references-count":51,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022,11]]}},"alternative-id":["533"],"URL":"https:\/\/doi.org\/10.1007\/s40272-022-00533-y","relation":{},"ISSN":["1174-5878","1179-2019"],"issn-type":[{"value":"1174-5878","type":"print"},{"value":"1179-2019","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,28]]},"assertion":[{"value":"16 August 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 September 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This work was supported by Janssen Research & Development, LLC. Janssen Research & Development, LLC had a role in the trial design; collection, analysis, and interpretation of data; writing of the report; and the decision to submit the article for publication.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Jocelyn H. Leu, Michael Clark, Karen Bensley, Kathleen G. Lomax, Katherine Berezny, and Zhenhua Xu are employees of Janssen Research & Development, LLC, a subsidiary of Johnson & Johnson, and may own stock in Johnson & Johnson. Honghui Zhou was an employee of Janssen Research & Development, LLC, a subsidiary of Johnson & Johnson, at the time the work was conducted and may own stock in Johnson & Johnson; Dr. Zhou is currently an employee at Elevar Therapeutics, Inc, Salt Lake City, UT, USA.\u00a0Natalie J. Shiff is an employee of Janssen Scientific Affairs, LLC, a subsidiary of Johnson & Johnson; received salary support from the Childhood Arthritis and Rheumatology Research Alliance within the past 3 years; and owns or has owned stock in AbbVie, Gilead, Iovance, Johnson & Johnson, Novo-Nordisc, and Pfizer within the past 3 years. Robert M. Nelson is an employee of Johnson & Johnson and owns stock in Johnson & Johnson.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All trials included in these analyses were conducted and reported in accordance with the ethical principles originating in the Declaration of Helsinki and in accordance with International Council for Harmonisation Good Clinical Practice guidelines, applicable regulatory requirements, and in compliance with the respective protocols.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics"}},{"value":"All participants or legal guardians of participants in the clinical trials included in these analyses provided written informed consent.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publication"}},{"value":"The data-sharing policy of Janssen Pharmaceutical Companies of Johnson & Johnson is available at\n                      \n                      . As noted on this site, requests for access to the trial data can be submitted through Yale Open Data Access (YODA) Project site at\n                      \n                      .","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material (data transparency)"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"Conceptualization: JHL, NJS, KBen, KGL, KBer, RMN, HZ, ZX. Methodology: JHL, MC, KBen, KGL, KBer, RMN, HZ, ZX. Data collection and\/or analysis: JHL, NJS, MC, KBen, KGL, KBer, HZ, ZX. Data interpretation: JHL, NJS, MC, KBen, KGL, KBer, RMN, HZ, ZX. Manuscript preparation, review, and editing: All authors. All authors approved the final version of the manuscript for publication.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}